Tarsus Pharmaceuticals Inc (NAS:TARS)

$ 28.93 1.38 (5.01%) Market Cap: 1.09 Bil Enterprise Value: 825.02 Mil PE Ratio: 0 PB Ratio: 3.97 GF Score: 60/100

Q1 2024 Tarsus Pharmaceuticals Inc Earnings Call Transcript
May 08, 2024

$37.35 (-1.79%)

Earnings
Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Feb 27, 2024

$39.22 (+18.28%)

Earnings
Q3 2023 Tarsus Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2023

$15.57 (-5.86%)

Earnings
Tarsus Pharmaceuticals Inc To Discuss XDEMVY Approved For The Treatment Of Demodex Blepharitis Call Transcript
Jul 25, 2023
Tarsus Pharmaceuticals Inc To Discuss Creating the Next Blockbuster Category in Eye Care Call Transcript
Jun 15, 2023
Tarsus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Tarsus Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2023
Tarsus Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Tarsus Pharmaceuticals Inc To Discuss Revolutionizing Treatment For Demodex Blepharitis Patients Call Transcript
Feb 08, 2022
Tarsus Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 08, 2021
Tarsus Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Tarsus Pharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021
Tarsus Pharmaceuticals Inc Saturn-1 Pivotal Trial Topline Results Call Transcript
Jun 21, 2021

Tarsus Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript

Jul 14, 2021 / 05:30PM GMT

Release Date Price: $26.11 (-5.84%)

Transcript

Matthew Kaplan

Ladenburg Thalmann & Co. Inc. - Analyst

It's my pleasure to introduce our next presenting company, Tarsus. Presenting for the Company today will be the CEO, Bobby Azamian. Bobby, thank you for taking part in our conference today. And I'm going to hand the podium over to you and give you a chance to present the Company, and then hopefully, we will have time for questions after your introduction.

Bobby Azamian

Tarsus Pharmaceuticals, Inc. - President and CEO

Thank you, Matt. Really a pleasure to be with you here today. And I'm excited to introduce the audience -- or update the audience, depending on the investors listening to Tarsus, in what we're up to. So I will be making forward-looking statements.

And I wanted to start with our vision and mission. So from day 1, we've been focused on really charting new ground and developing a brand-new drug for a brand-new indication. That's TP-03 for Demodex blepharitis. And I started the Company with that mission, to not only deliver a really important new therapy but also a scalable company

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.